Drugs / Visilizumab
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00006009 | Apr 2001 → Oct 2003 | lymphoma, small intestine cancer | Stanford University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00267306 | Jan 2004 → Dec 2006 | ulcerative colitis | Facet Biotech | Completed | No outcome recorded |
| Phase 1/2 | NCT00032292 | Mar 2002 → Aug 2006 | acute graft versus host disease | Facet Biotech | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00720629 | Dec 2007 → Dec 2013 | graft versus host disease | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00307827 | Apr 2006 → Nov 2007 | ulcerative colitis | Abbott | Terminated | No outcome recorded |
| Phase 2 | NCT00267722 | Feb 2005 → Dec 2006 | Crohn disease | Facet Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00267709 | Feb 2005 → Dec 2006 | Crohn disease | Facet Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00032279 | Mar 2002 → ? | acute graft versus host disease | Fred Hutchinson Cancer Center | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00279435 | Aug 2006 → Aug 2007 | ulcerative colitis | Facet Biotech | Terminated | No outcome recorded |
| Phase 2/3 | NCT00032305 | Mar 2002 → Nov 2005 | ulcerative colitis | Facet Biotech | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04722952 | May 2021 → Jan 2023 | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 3 | NCT00502294 | — | — | Facet Biotech | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Visilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04722952 ↗ |
| Known as | HuM291 | “Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis.” PMID 19714757 ↗ Apr 20101“Visilizumab (HuM291; Nuvion®)” NCT00502294 ↗ |
| Known as | Nuvion | “A Phase II, Multicenter Clinical Trial Evaluating the Use of Humanized Monoclonal Anti-CD3 Antibody Visilizumab(Nuvion) as Second-line Therapy for Glucocorticoid-Refractory,...” NCT00032279 ↗1“Visilizumab (HuM291; Nuvion®)” NCT00502294 ↗ |
| Action | Deplete | “All patients exhibited a rapid decrease in circulating CD4(+) T-cell counts” PMID 17920064 ↗ Aug 2007 |
| Action | Inhibit | “T-cell surface glycoprotein CD3 epsilon chain inhibitor” CHEMBL2108811 ↗ |
| Modality | Monoclonal antibody | “Humanized Monoclonal Anti-CD3 Antibody” NCT00032279 ↗ |
| Route | Intravenous | “administered intravenously” PMID 17920064 ↗ Aug 2007 |
| Target | CD3E | “T-cell surface glycoprotein CD3 epsilon chain inhibitor” CHEMBL2108811 ↗ |